The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 21.25
Bid: 20.50
Ask: 21.50
Change: 0.25 (1.19%)
Spread: 1.00 (4.878%)
Open: 20.75
High: 21.25
Low: 19.75
Prev. Close: 21.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Angle soars on clinical tests; Likewise sales up

Thu, 04th Jan 2024 10:43

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

----------

AIM - WINNERS

----------

Angle PLC, up 62% at 21.50 pence, 12-month range 9.07p-48.50p. Shares in the medical diagnostics firm soar after it unveils "breakthrough" clinical results from DNA molecular analysis of cancer patient blood samples that "provide a unique insight into the progression of each patient's cancer and how this may be treated". Angle says the results "highlight the potential for the Parsortix system to identify key variants [of] DNA mutations missed by other approaches to help guide treatment decisions." Chief Executive Officer Andrew Newland says: "Today's breakthrough is the critical next step post the [US Food & Drug Administration] clearance to show in a sample-to-answer format the potential clinical value of [next generation sequencing] molecular analysis on a repeat basis of living cancer cells harvested from patient blood samples. Angle is committed to delivering transformational benefits to cancer patients through a simple blood test. This is a major step in this process."

----------

Likewise Group PLC, up 15% at 23.00p, 12-month range 14.00p-28.00p. The domestic and commercial floor coverings distributor says 2023 gross sales revenue rose 14% to GBP140.2 million from a year earlier, while sales in Likewise Floors rose 29%. It says these increases are "particularly positive given the macro economic headwinds and subsequent challenging market conditions". Likewise says 2023 sales revenue is ahead of current market expectations and underlying profitability is expected to be in line with market expectations, reflecting the continued investment in the future of the business. Looking ahead, it is confident of achieving current market expectations for 2024, as it "continues to develop its position in the UK flooring market".

----------

AIM - LOSERS

----------

Landore Resources Ltd, down 13% at 2.70p, 12-month range 2.33p-18.37p. The Ontario, Canada-focused precious and base metal project explorer and developer raises GBP600,000 via a placing and subscription of 25.0 million new shares at a price of 2.4p each. The net proceeds of the fundraising will be used for general working capital purposes and to progress its strategy towards advancing its flagship BAM gold project at the Junior Lake property in northwestern Ontario. It says the new shares represent around 17% of its enlarged share capital. Landore also says Chief Executive Officer Claude Lemasson resigns with immediate effect, with Glenn Featherby assuming the role of interim CEO.

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
14 Aug 2020 12:41

Angle's Parsortix Able To Predict Patients' Response To Treatment

Angle's Parsortix Able To Predict Patients' Response To Treatment

Read more
20 Jul 2020 20:03

IN BRIEF: Angle Notes Study Showing "Key Capabilities" Of Parsortix

IN BRIEF: Angle Notes Study Showing "Key Capabilities" Of Parsortix

Read more
20 Jul 2020 10:16

Angle's 'Parsortix' advantageous in breast cancer in new research

(Sharecast News) - Angle announced on Monday that the University of Southern California (USC) has published peer-reviewed results of new work undertaken in metastatic breast cancer (MBC), highlighting advantages of a 'Parsortix' liquid biopsy, compared to standard-of-care tissue biopsy.

Read more
25 Jun 2020 12:22

Angle Progresses On Parsortix And De Novo Clearance From US Regulator

Angle Progresses On Parsortix And De Novo Clearance From US Regulator

Read more
18 Jun 2020 16:05

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
10 Jun 2020 16:41

IN BRIEF: Haydale Graphene Appoints Former AIM Market COO To Board

IN BRIEF: Haydale Graphene Appoints Former AIM Market COO To Board

Read more
12 May 2020 18:54

Angle's Parsortix Could Be Used To Pick MET Inhibitor Trial Subjects

Angle's Parsortix Could Be Used To Pick MET Inhibitor Trial Subjects

Read more
12 May 2020 08:58

Angle upbeat on recent research using 'Parsortix'

(Sharecast News) - Liquid biopsy company Angle announced on Tuesday that the liquid biopsy analysis unit at the Health Research Institute of Santiago in Spain has published results of new work undertaken in head and neck cancer and non small cell lung cancer, on the potential utility of a liquid biopsy-based strategy to assess MET alterations on circulating tumour cells (CTCs).

Read more
28 Apr 2020 12:28

UK TRADING UPDATE SUMMARY: Zenith Latest To Join Global Drive For PPE

UK TRADING UPDATE SUMMARY: Zenith Latest To Join Global Drive For PPE

Read more
28 Apr 2020 10:03

Angle works with skeleton R&D crew during lockdown

(Sharecast News) - Biopharmaceuticals group Angle said on Tuesday that progress had been impeded by the Covid-19 outbreak as the firm worked with a research and development skeleton crew in Guildford.

Read more
31 Mar 2020 12:21

UK TRADING UPDATE SUMMARY: Synairgen Starts Covid-19 Treatment Trial

UK TRADING UPDATE SUMMARY: Synairgen Starts Covid-19 Treatment Trial

Read more
31 Mar 2020 09:40

Angle UK, US, Canada operations 'severely disrupted' by Covid-19

(Sharecast News) - Liquid biopsy company Angle said on Tuesday that operations in the UK, US and Canada had all been "severely disrupted" by the Covid-19 pandemic.

Read more
3 Mar 2020 18:58

Angle Parsortix Test Used To Help Discover Brain Metastasis

Angle Parsortix Test Used To Help Discover Brain Metastasis

Read more
27 Feb 2020 14:09

Angle's Parsortix Beats Others In Assessing Kidney Cancer Patients

Angle's Parsortix Beats Others In Assessing Kidney Cancer Patients

Read more
27 Feb 2020 12:42

Angle upbeat on recent Parsortix research out of Italy

(Sharecast News) - Liquid biopsy company Angle announced on Thursday that Istituto Nazionale Tumori di Milano in Milan, Italy, has published results of work assessing the performance of its 'Parsortix' system in renal cell carcinoma (RCC), demonstrating key advantages of Parsortix.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.